Latest early-stage breast cancer Stories
SAN ANTONIO, Dec. 13, 2010 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from seven new studies focusing on its multigene Oncotype DX(Â®) breast cancer test, which has helped guide treatment decisions in more than 175,000 breast cancer patients worldwide.
Postmenopausal women fighting a specific form of breast cancer may get some help through innovative use of two enzyme-inhibiting drugs.
REDWOOD CITY, Calif., Dec. 3, 2010 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B.
SAN DIEGO, Nov.
SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Accuray Incorporated, (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment.
BARCELONA, Spain, Sept. 13 /PRNewswire/ -- Xoft, Inc., the pioneer of localized, isotope-free radiation treatment delivered in minimally-shielded clinical settings, today announced the introduction of the AxxentÂ® Electronic Brachytherapy, eBx(TM) System to physicians and distributors in Europe.
The American Society for Radiation Oncology (ASTRO) has released evidence-based guidelines to define appropriate fractionation of whole breast irradiation (WBI), finding that hypofractionated (HF) WBI is effective for many patients with early-stage breast cancer.
SUNNYVALE, Calif., June 14 /PRNewswire/ -- The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the AxxentÂ® Electronic Brachytherapy, eBx(TM) System.
Growing body of data suggests Chronix's serum DNA assays may represent a new approach to diagnostics and prognostics in cancer and other diseases.
CHICAGO, June 5 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.
- A woman chauffeur.
- A woman who operates an automobile.